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Pancreatic apoptosisBackground: Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance, hyperinsulinaemia
and hyperglycaemia. Increased glucose production through abnormally elevated hepatic gluconeogenesis
is central to the manifestation of hyperglycaemia in T2DM. Metformin corrects hyperglycaemia mainly
through inhibition of gluconeogenesis. Sirtuin 1 (SIRT1) has been identified as regulator of gluconeogenic
gene expression. The present study aimed to evaluate the effect of metformin on SIRT1 level and activity
in liver and pancreas of diabetic rats. Further, the possible role of SIRT1 on metabolic disorders associated
with diabetes mellitus, including serum levels of glucose, insulin, triglyceride (TG) and high density
lipoprotiens (HDL), will be explored.
Methods: Thirty-two male albino rats were divided into control group (GpI), diabetic (DM) group (GpII),
(metformin + DM) group (GpIII) administered 120 mg/kg metformin daily for 1 month before induction
of diabetes, (DM + metformin) group (GpIV) administered 250 mg/kg metformin daily for 1 month after
induction of diabetes. At the end of the study, BMI%, serum levels of glucose, insulin, TG and HDL, HOMA,
SIRT1 level and activity in liver and pancreas and pancreatic DNA ladder were assessed.
Results: Our results showed significant decrease in serum glucose, insulin and TG levels and HOMA; sig-
nificant increase in HDL level and SIRT1 level and activity in liver and pancreas beside the marked disap-
pearance of pancreatic apoptosis in GpIII & IV relative to GpII. Regarding BMI%, it showed no significant
changes in GpIV relative to GpII. No significant change was recorded between GpIII and GpIV regarding all
studied parameters except on serum TG.
Conclusion: Lowered SIRT1 in diabetes was improved by the administration of Metformin. Consequently,
the pathophysiological disorders associated with T2DM were improved.
 2017 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
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Prevalence of type 2 diabetes mellitus (T2DM) has increased
dramatically over the past four decades. T2DM is characterized
by insulin resistance, hyperinsulinemia and hyperglycemia. Also,
abnormal elevated hepatic gluconeogenesis is central to the man-
ifestation of hyperglycemia in T2DM.42
Beside, an increase in beta cell apoptosis is an important factor
contributing to beta cells loss and the onset of T2DM.46 There is
in vitro evidence that gluco-toxicity and lipo-toxicity exert syner-
gistic effects to impair the secretory function of beta cells and to
promote apoptosis in T2DM.16
Sirtuin 1 (SIRT1): a homolog of the yeast protein Silent Informa-
tion Regulator 2 (Sir2), encodes the NAD (nicotinamide adenine
dinucleotide) dependent histone deacetylase enzyme. It may play
a key role in stress responses and cellular metabolism, through
deacetylating a variety of substrates, including histones, transcrip-
tion factors and coregulators, to regulate target gene expression
both positively and negatively.35
SIRT1 activators improve whole-body glucose homeostasis and
insulin sensitivity in adipose tissue, skeletal muscle and liver. Thus,
SIRT1 activation is a promising new therapeutic approach for treat-
ing diseases of ageing such as T2DM.35
Metformin, the primary therapeutic agent for T2DM patients,
corrects hyperglycemia and hyperinsulinemia predominantly by
enhancing insulin-mediated suppression of hepatic glucose pro-
duction and enhancing insulin-stimulated glucose uptake by skele-
tal muscles.25
Caton et al.,9 reported that the activation of hepatic AMPK by
metformin will consequently increase SIRT1 activity. This will
result in reduced levels and activity of the coactivators cAMP-
response element binding protein-regulated transcription coacti-
vator 2 (TORC2) or CRTC2) level – mediated gluconeogenesis, thus
lowering plasma glucose and insulin.
In our previous work on similar model, we investigated the pos-
sible influence of 30% caloric restriction on SIRT1 in diabetic rats,and we found that both pre-diabetes CR and post-diabetes CR
regimens were associated with significant improvement of
insulin resistance and its subsequent hyperglycemia beside their
role in attenuation of the marked decrease of SIRT1 in the liver
and pancreas that accompanied the induction of type 2 diabetes
mellitus.18
In the present study, we investigated the effect of metformin on
SIRT1 level and activity in liver and pancreas of diabetic rats. Fur-
ther, the possible role of SIRT1 on metabolic disorders associated
with diabetes mellitus will be explored.
2. Material and methods
2.1. Animals and experimental design
32 male albino rats, approximately aged 8 weeks and weighed
150–200 gram were housed in wire mesh cages at room tempera-
ture under ordinary living conditions. Rats were fed for whole per-
iod of study on standard laboratory rat diet (standard rat chow),
Veterinary care was provided by laboratory animal house unit of
faculty of Medicine, Cairo University.
Animals were randomly divided into the following 4 groups:
Group I: control group (n = 8): rats were injected citrate buffer and
no further medications or life style modifications were applied.
Group II: diabetic (DM) group (n = 8): rats were fasted for 12-h
before induction of diabetes. Streptozotocin (STZ) was freshly dis-
solved in 0.05 M citrate buffer, pH 4.5 and injected intraperi-
toneally in a single dose of 40 mg/kg.4 No further treatment or
dietary modification was applied for 1 month.
Group III: metformin + diabetes (metformin + DM) group (n = 8):
rats administered 120 mg/kg metformin orally once daily9 for
1 month before induction of diabetes and sacrificed after 3 days.
Group IѴ: diabetes +metformin (DM +metformin) group (n = 8):
rats were subjected for induction of diabetes followed by adminis-
tration of 250 mg/kg metformin once daily (Foretz et al., 2010)
for1 month.
Table 1
Primer sequences used for RT-PCR.
Primer Sequence
Sirt1 Forward primer: 5-. . .. . .. . .. . .. . .. . .-3
Reverse primer: 5-. . .. . .. . .. . .. . ..-3
GAPDH forward: 50-CTCCCATTCTTCCACCTTTG-30
reverse: 50-CTTGCTCTCAGTATCCTTGC-30
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grams & their naso-anus lengths in cm while the rats were anes-
thetized with ether were measured to calculate their body mass
index (BMI) as an index of obesity according to an equation formu-
lated by17:
BMI ¼ Cubic root of weight in grams
 1000=Naso-Anal length in cms
Subsequently, fasting blood samples were withdrawn retro-
orbital using a capillary tube in for assessment of fasting serum
glucose, fasting serum insulin, (HOMA-IR), serum triglycerides
(TG) and serum high density lipoprotein (HDL) levels. Animals
were then scarified followed by rapid excision of liver and pancreas
for further assessment of SIRT1 level and activity and pancreatic
DNA ladder.
Serum glucose level was tested by kits supplied by ‘‘Diamond
Diagnostics”.53 The serum insulin concentrations were measured
by enzyme immunoassay using the rat insulin ELISA kits,22 and
HOMA-IR index was calculated as the product of fasting serum
insulin (lIU/L) and fasting serum glucose (mmol/L) divided by
22.5. HOMA more than 4.0 is diagnostic of insulin resistance.19
The serum triglyceride was measured by quantitative – enzy-
matic –colorimetric determination of triglycerides in serum.5 How-
ever, HDL-Cholesterol is obtained through selective precipitation
of LDL and VLDL lipoproteins, thus HDL lipoproteins remain in
solution. HDL-Cholesterol in supernatant was treated as a sample
for cholesterol assay, and after many reactions a colored compound
was yielded. The color was measured at 546 nm and was propor-
tional to HDL-Cholesterol concentration in sample when used as
directed.41
Abcam’s SIRT1 Activity Assay Kit (Fluorometric) (ab156065)
measures the activity of SIRT1 by the basic principle of changing
a SIRT1 reaction into the activity of the protease. In order to mea-
sure the enzyme activity of SIRT1, which is the NAD dependent his-
tone deacetylase, and its homolog, this kit is designed so that the
activity of NAD dependent histone deacetylase can be measured
under existence of Trichostatin A, which is the powerful inhibitor
of HDACs.58
2.2. Detection of SIRT1 gene expression by real time-polymerase chain
reaction (real time-PCR) in liver and pancreas43
2.2.1. RNA isolation and reverse transcription
RNA was extracted from the hepatic and pancreatic tissue
homogenate using the RNeasy plus mini kit (Qiagen, Venlo, The
Netherlands), according to the manufacturer’s instructions. Geno-
mic DNA was eliminated by a DNase-on-column treatment sup-
plied with the kit. The RNA concentration was determine
spectrophotometrically at 260 nm using the NanoDrop ND-1000
spectrophotometer (ThermoFisher scientific, Waltham, USA) and
RNA purity was checked by means of the absorbance ratio at
260/280 nm. RNA integrity was assessed by electrophoresis on
2% agarose gels. (1 mg) of RNA were used in the subsequent cDNA
synthesis reaction, which was performed using the Reverse Tran-
scription System (Promega, Leiden, The Netherlands). Total RNA
was incubated at 70 C for 10 min to prevent secondary structures.
The RNA was supplemented with MgCl2 (25 mM), RTase buffer
(10X), dNTP mixture (10 mM), oligod(t) primers, RNase inhibitor
(20 U) and AMV reverse transcriptase (20 U/ml). This mixture was
incubated at 42 C for 1 h.
2.2.2. Quantitative real time PCR
qPCR was performed in an optical 96-well plate with an ABI
PRISM 7500 fast sequence detection system (Applied Biosystems,
Carlsbad, California) and universal cycling conditions min 95 C,40 cycles of 15 s at 95 C and 60 s at 60 C). Each 10 ml reaction con-
tained 5 ml
SYBR Green Master Mix (Applied Biosystems), 0.3 ml gene-
specific forward and reverse primers (10 mM), 2.5 ml cDNA and
1.9 ml nuclease-free water. The sequences of PCR primer pairs used
for each gene are shown in Table 1. Data were analyzed with the
ABI Prism sequence detection system software and quantified
using the v17 Sequence Detection Software from PE Biosystems
(Foster City, CA). Relative expression of studied genes was calcu-
lated using the comparative threshold cycle method. All values
were normalized to the GAPDH genes R1.282.3. Detection of DNA fragmentation11
DNA was extracted from the pancreas using the kit supplied by
Qiagen according to the manufacturer’s instructions. Then Gel elec-
trophoresis was done for extracted DNA.2.3.1. Statistical analysis
Data were coded and entered using the statistical package SPSS
version 15. Data were summarized using mean, standard deviation
and % change for the quantitative variables. Comparisons between
groups were done using analysis of variance (ANOVA) and multiple
comparisons (Post Hoc test) for the quantitative variables. P-values
less than 0.05 were considered as statistically significant.103. Results
3.1. Comparison between BMI%, serum glucose (mmol/L), serum
insulin (mIU/L) levels and HOMA in all studied groups
As observed in Table 2, BMI% was insignificantly increased by
6.47% (P = 0.290) while fasting serum glucose (mmol/L), serum
insulin (mIU/L) and (HOMA) levels were significantly increased
(P = 0.000) by 163.04%, 79.16% and 378.70% respectively in diabetic
group (GpII) compared to control group (GpI). Mean values in dia-
betic group were respectively 280.06 ± 19.8; 12.81 ± 1.94;
17.88 ± 1.23 and 10.34 ± 2.17 versus 263.05 ± 9.68; 4.87 ± 0.18;
9.98 ± 1.24 and 2.16 ± 0.24 in control group.
As shown in Table 2, administration of metformin for 1 month
before induction of diabetes was associated with significant
improvement in BMI% (P = 0.001), serum glucose level, serum insu-
lin level and HOMA (P = 0.000) in which these parameters were
lower than diabetic group (GpII) by 17.35%, 50.04%, 27.74% and
63.73% respectively. Mean values of BMI%, glucose, insulin and
HOMA were 249.92 ± 14.64, 6.40 ± 1.15, 12.92 ± 2.04 and
3.75 ± 1.26 in GpIII versus 280.06 ± 19.8, 12.81 ± 1.94,
17.88 ± 1.23 and 10.34 ± 2.17 in GpII. Interestingly, compared to
control values, BMI%, serum glucose level and HOMA in GpIII
showed a non-significant higher difference (P > 0.05) of 4.99%,
31.42% and 73.61% respectively while insulin was significantly
higher by 29.46% (P = 0.008). Mean values of BMI%, glucose, insulin
and HOMA were respectively 249.92 ± 14.64, 6.40 ± 1.15,
12.92 ± 2.04 and 3.75 ± 1.26 in GpIII versus 263.05 ± 9.68;
4.87 ± 0.18; 9.98 ± 1.24 and 2.16 ± 0.24 in GpI.
Table 2
Changes of BMI%, fasting serum glucose (mmol/L), fasting serum insulin (mIU/L) levels and HOMA in all studied groups.
Parameter GpI (control) GpII (DM) GpIII (metformin + DM) GpIV (DM +metformin)
BMI% 263.05 ± 9.68 280.06 ± 19.8 249.92* ± 14.64 267.95 ± 10.31
Glucose (mmol/L) 4.87 ± 0.18 12.81 ± 1.94 6.40* ± 1.15 6.77* ± 1.53
Insulin(mIU/L) 9.98 ± 1.24 17.88 ± 1.23 12.92* ± 2.04 13.11* ± 1.78
HOMA 2.16 ± 0.24 10.34 ± 2.17 3.75* ± 1.26 4.04* ± 1.52
Values are represented as mean ± SD.
N.B: control group results have been reused from our previous publication.18
* Significant change comparing corresponding values to GpII.
 Significant change comparing corresponding values to GpI.
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1 month after inducing diabetes in GpIV had no significant effect
(P > 0.05) on BMI% relative to both diabetic and control groups.
Mean values were 267.95 ± 10.31 in GpIV versus 280.06 ± 19.8 in
GpII and 263.05 ± 9.68 in GpI. However, a significant improvement
(P = 0.000) regarding fasting serum glucose (mmol/L), fasting
serum insulin (mIU/L) and HOMA were observed in GpIV compared
to GpII. They were significantly decreased by 47.15%; 26.67% and
60.93% respectively in GpIV compared to GpII.
On the other hand, relative to GpI, fasting serum glucose and
HOMA in GpIII showed insignificant difference (P > 0.05); while
serum insulin (mIU/L) was significantly higher by 31.36%
(P = 0.004) in GpIII. Mean values for serum glucose, insulin and
HOMA were respectively 6.77 ± 1.53; 13.11 ± 1.78; 4.04 ± 1.52 in
GpIV, versus 12.81 ± 1.94; 17.88 ± 1.23; 10.34 ± 2.17 in GpII and
4.87 ± 0.18; 9.98 ± 1.24; 2.16 ± 0.24 in GpI.
Our study showed that although the administration of met-
formin before induction of diabetes had a higher improving effect
on fasting serum glucose, insulin and HOMA levels than post-
diabetic metformin, yet this difference was insignificant (P > 0.05).
Mean values were respectively 6.77 ± 1.53; 13.11 ± 1.78;
4.04 ± 1.52 in GpIV; 6.40 ± 1.15; 12.92 ± 2.04; 3.75 ± 1.26 in GpIII
versus 12.81 ± 1.94, 17.88 ± 1.23; 10.34 ± 2.17 in GpII as shown in
Table 2. Regarding BMI%, it revealed no significant change in
(P > 0.05) comparing corresponding mean values in GpIV
(267.95 ± 10.31) versus GpIII (249.92 ± 14.64).3.2. Comparison between the serum TG (mg/dl) and HDL (mg/dl) levels
in all studied groups
As shown in Table 3, serum TG level (mg/dl) was significantly
increased by 68.56% (P = 0.000), while serum HDL level (mg/dl)
was significantly decreased by 37.2% (P = 0.000) in diabetic group
compared to control group. Mean values were 102.18 ± 12.48;
31.72 ± 1.65 in GpII versus 60.62 ± 12.54; 50.52 ± 4.08 respectively
in GpI.
Similar to its beneficial effect on BMI%, serum glucose, insulin
and HOMA, the pre-diabetic metformin lowered significantly the
serum TG (mg/dl) level by 22.70% (P = 0.004) and increased signif-
icantly the serum HDL (mg/dl) level by 24.53% (P = 0.041). Mean
values attained 78.99 ± 8.81 and 39.50 ± 5.07 respectively in GpIII
versus 102.18 ± 12.48 and 31.72 ± 1.65 respectively in GpII.Table 3
Changes of TG (mg/dl) and HDL (mg/dl) levels in all studied groups.
Parameter Gp I (control) Gp II (DM)
TG (mg/dl) 60.62 ± 12.54 102.18 ± 12.48
HDL (mg/dl) 50.52 ± 4.08 31.72 ± 1.65
Values are represented as mean ± SD.
* Significant change comparing corresponding values to GpII.
 Significant change comparing corresponding values to GpI.
1 Significant change comparing corresponding values in GpIV versus GpIII.Despite this beneficial effect, full recovery in serum TG and HDL
levels was not achieved. A significant difference by 30.30%
(P = 0.042) and 21.81% (P = 0.001) existed respectively comparing
GpIII versus GpI. Mean values were 78.99 ± 8.81; 39.50 ± 5.07 in
GpIII versus 60.62 ± 12.54; 50.52 ± 4.08 respectively in GpI
(Table 3).
As observed in Table 3, a significant improvement (P = 0.000) in
serum TG by 41.97% and HDL levels (mg/dl) by 39.9% was recorded
comparing corresponding values of post diabetic metformin
administration in GpIV relative to GpII. Even more, compared to
control group, no significant difference was noticed (P > 0.05).
Mean values of serum TG and HDL levels were respectively
59.30 ± 12.30; 44.38 ± 7.46 in GpIV versus 102.18 ± 12.48;
31.72 ± 1.65 in GpII and 60.62 ± 12.54; 50.52 ± 4.08 in GpI.
On the other hand, comparing the effect of pre-diabetic versus
post-diabetic metformin, our results showed that TG level in GpIV
was significantly (P = 0.022) lower by 24.93% relative to GpIII.
However, no significant difference (P > 0.05) was recorded as
regards serum HDL comparing both groups. Mean values were
respectively 59.30 ± 12.30; 44.38 ± 7.46 in GpIV versus
78.99 ± 8.81; 39.50 ± 05.07 in GpIII (Table 3).3.3. Comparison between the SIRT1 level and SIRT1 activity (ng/dl) in
the liver and pancreas of all studied groups
As shown in Table 4, Figs. 1 and 2, SIRT1 level and activity in the
liver were significantly (P = 0.000) decreased by 54.84% and 55.81%
respectively following induction of diabetes. Mean values were
0.98 ± 0.22; 2.28 ± 0.58 in GpII versus 2.17 ± 0.35; 5.16 ± 1.28 in
GpI respectively.
We noticed that pre-diabetic metformin was significantly effec-
tive to counteract the reduction of SIRT1 level and activity in the
liver and pancreas of diabetic group. Our results for GpIII showed
a significant improvement in SIRT1 level and activity in liver (ng/
dl) by 51.02% (P = 0.005), 154.82% (P = 0.000) respectively relative
to GpII. Even more, no significant difference was detected compar-
ing GpIII to control group (P > 0.05). Mean values of SIRT1 level and
activity in liver were respectively 1.48 ± 0.41; 5.81 ± 0.75 in GpIII
versus 0.98 ± 0.22; 2.28 ± 0.58 in GpII and 2.17 ± 0.35; 5.16 ± 1.28
in GpI.
As shown in Table 4, Figs. 3 and 4, SIRT1 level and activity in
pancreas were significantly decreased by 59.3% (P = 0.009) andGpIII (metformin + DM) GpIV (DM +metformin)
78.99* ± 8.81 59.30*1 ± 12.30
39.50* ± 5.07 44.38* ± 7.46
Table 4
Changes of SIRT1 level (ng/dl) and SIRT1 activity (ng/dl) in liver and pancreas in all studied groups.
Parameter GpI (control) GpII (DM) GpIII (metformin + DM) GpIV (DM + metformin)
SIRT1 level (liver) 2.17 ± 0.35 0.98 ± 0.22 1.48* ± 0.41 1.74* ± 0.33
SIRT1 activity (liver) 5.16 ± 1.28 2.28 ± 0.58 5.81* ± 0.75 7.44* ± 1.12
SIRT1 level (pancreas) 1.72 ± 0.55 0.70 ± 0.25 1.94* ± 0.57 1.90* ± 0.87
SIRT1 activity (pancreas) 8.24 ± 1.13 2.99 ± 1.13 7.04* ± 1.85 6.73* ± 1.80
Values are represented as mean ± SD.
N.B: control group results have been reused from our previous publication.18
1Significant change comparing corresponding values in GpIV versus GpIII
* Significant change comparing corresponding values to GpII.
 Significant change comparing corresponding values to GpI.
Fig. 1. Changes of SIRT1 level (ng/dl) in liver in all studied groups.
Fig. 2. Changes of SIRT1 activity (ng/dl) in liver in all studied groups.
Fig. 3. Changes of SIRT1 level (ng/dl) in pancreas in all studied groups.
Fig. 4. Changes of SIRT1 activity (ng/dl) in pancreas in all studied groups.
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2.99 ± 1.13 in GpII versus 1.72 ± 0.55; 8.24 ± 1.13 in GpI
respectively.
We also recorded significant elevation of SIRT1 level and activ-
ity in pancreas in GpIII by 177.14% (P = 0.001) and 135.46%
(P = 0.000) relative to GpII and showed insignificant difference
(P > 0.05) compared to control group. Mean values were respec-tively 1.94 ± 0.57; 7.4 ± 1.85 in GpIII versus 0.70 ± 0.25;
2.99 ± 1.13 in GpII and 1.72 ± 0.55; 8.24 ± 1.13 in GpI (Table 4).
Also, metformin intake for 1 month after induction of diabetes
induced a significant enhancement in SIRT1 level and activity in
the liver of diabetic rats. Data showed a significant increase
(P = 0.000) in SIRT1 level and activity in liver by 77.55% and
226.32% respectively in GpIV relative to diabetic group. Although
relative to control group, SIRT1 level in liver of GpIV showed
insignificant difference (P > 0.05), yet a significant difference of
44.19% still existed (P = 0.003) regarding the SIRT1 activity. Mean
values were respectively 1.74 ± 0.33; 7.44 ± 1.12 in GpIV versus
0.98 ± 0.22; 2.28 ± 0.58 in GpII and 2.17 ± 0.35; 5.16 ± 1.28 in GpI
(Table 4).
Similarly, the SIRT1 level and activity (ng/dl) in pancreatic tis-
sues of GpIV exhibited significant elevation by 171.43%
(P = 0.001) and 125.08% (P = 0.000) respectively compared to GpII.
Moreover, no significant difference was detected relative to control
group (P > 0.05). Mean values were respectively 1.90 ± 0.87;
6.73 ± 1.80 in GpIV versus 0.70 ± 0.25; 2.99 ± 1.13 in GpII and
1.72 ± 0.55; 8.24 ± 1.13 in GpI (Table 4).
Interestingly, our results demonstrated that the difference in
the improving effect of pre-diabetic metformin relative to post-
diabetic metformin was insignificant (P > 0.05). Mean values of
SIRT1 level and activity in liver were respectively1.74 ± 0.33;
7.44 ± 1.12 in GpIV versus 1.48 ± 0.41; 5.81 ± 0.75 in GpIII. As well,
mean values of SIRT1 level and activity in pancreas were respec-
tively 1.90 ± 0.87; 6.73 ± 1.80 in GpIV versus 1.94 ± 0.57;
7.04 ± 1.85 in GpIII (Table 4).
3.4. Changes in DNA ladder among all studied groups
The DNA fragmentation pattern was monitored in treated and
untreated pancreatic tissue on agarose gel electrophoresis. Necro-
tic strand breaks/streaking DNA was observed diabetic group
(GpII), but not in groups pretreated with metformin (GpIII) prior
to STZ exposure and also in diabetic rats treated with metformin
(GpIV) as revealed in Fig. 5.
Fig. 5. DNA fragmentation pattern in pancreas among all studied groups.
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icant inverse relationship between (SIRT1 level and activity in liver
and SIRT1 level in pancreas) and (BMI%, serum levels of glucose,
insulin and TG, and HOMA) meanwhile the formers showed signif-
icant positive correlation with serum HDL level.
On the contrary, BMI%, serum levels of glucose, insulin, TG and
HDL, and HOMA were not significantly correlated with the pancre-
atic SIRT1activity.
However, regarding group III (metformin + DM) there was sig-
nificant decrease in (BMI%, serum levels of insulin, TG and HDL,
and HOMA) associated with (the elevation of SIRT1 level and activ-
ity in the liver and pancreas). Meanwhile the later showed signifi-
cant positive correlation with serum HDL level. Although the
serum glucose level was also significantly decreased parallel to
the increase in SIRT1 activity in both liver and pancreas in rats
received metformin before induction of diabetes yet its level was
insignificantly correlated with SIRT1 level in liver and pancreas.
On the other hand, the elevated SIRT1 level and activity in hep-
atic and pancreatic tissues of diabetic rats following administration
of metformin over 1 month was associated with significant
diminution of BMI%, serum levels of glucose, insulin and TG, and
HOMA) and significant increase in serum HDL level respectively .4. Discussion
The rising incidence of type 2 diabetes mellitus (T2DM) is a
major public health problem in industrialized countries and new
therapeutic strategies to treat and prevent T2DM are urgently
needed worldwide.51
Abnormal elevation of hepatic gluconeogenesis is central to the
onset of hyperglycaemia in patients with T2DM. Metformin cor-
rects hyperglycaemia through inhibition of gluconeogenesis, but
its mechanism of action is yet to be fully described.9
SIRT1 was originally identified as a NAD+-dependent histone
deacetylase, has been identified as regulator of gluconeogenic gene
expression.9. Growing evidence suggests that SIRT1 regulates
glucose-lipid metabolism through its deacetylase activity for many
known substrates. SIRT1 has also many roles in the metabolic
pathways through its direct or indirect involvement in insulin sig-
naling in insulin-sensitive organs, including adipose tissue, liver
and skeletal muscles.24 In addition, SIRT1 regulates insulin secre-
tion, adiponectin production, inflammation, gluconeogenesis and
oxidative stress, which together contribute to the development of
insulin resistance.30
The present work has been designed to investigate the possible
link of the action of metformin on SIRT1 in diabetic rats and if met-
formin could be a line of treatment that is helpful in re-establishing
the physiological relevant activity of SIRT1 known to be attenuated
with diabetes. We also attempted to test if it has any preventive
value through tempering of SIRT1 disorders associated with the
development ofT2DM.Therefore, we induced diabetes in eight adult male rats (GpII)
by single intra-peritoneal injection of 40 mg/kg STZ, a well-
known specific toxin causing pancreatic b-cell partial damage.4 It
was in agreement with our results, in which there was marked
pancreatic apoptosis obtained after induction of diabetes.
Consequently, the fasting serum glucose level was significantly
elevated, indicating hyperglycemia compared to control group.
Moreover, our results also showed a significant increase in fasting
serum insulin level and HOMA-IR confirming the characteristic
features of T2DM. Results may be explained by the occurrence of
insulin resistance in peripheral tissues especially skeletal muscles
regarding their importance in glucose homeostasis.
Our results were in agreement with Kadowaki et al.26 who sta-
ted that in streptozotocin (STZ)-induced diabetic rats, the number
of insulin receptors is increased, whereas the receptor tyrosine
kinase activity per unit of insulin binding is severely reduced.
While, Burant et al.6 suggested that peripheral insulin resistance
associated with streptozotocin induced DM, may be related to
modifications in insulin receptor structure and the glucose trans-
port system, resulting in impaired signal transmission.
Beside, obtained data for BMI% showed a non-significant
increase in diabetic group compared to control group. Our results
could be primarily explained by the significant insulin resistance
(hyperinsulinemia) which was in agreement with Takada et al.52
who reported that diabetes associated polyphagia may be the
cause of this non-significant weight change particularly that our
rats in GpII were fed ad libitum and they may need a longer dura-
tion to exhibit weight loss.
Insulin resistance and T2DM are associated with a clustering of
interrelated plasma lipid and lipoprotein abnormalities, which
include reduced HDL cholesterol and elevated TG levels.8 Similarly,
our results showed significant elevation of serumTG level by
68.56% and significant reduction of serum HDL level by 37.2% in
diabetic rats versus the control group.
As well, Krauss32 emphasized that insulin resistance may play a
pivotal role in the development of diabetic dyslipidemia by influ-
encing several factors. Increased efflux of free fatty acids from adi-
pose tissues and impaired insulin-mediated skeletal muscle uptake
of free fatty acids, increase fatty acids flux to the liver.
Beside, insulin resistance also increases hepatic lipase activity
which is responsible for hydrolysis of phospholipids in LDL and
HDL particles and leads to smaller and denser LDL particles and a
decrease in HDL.39
As Caton et al.9 demonstrated that SIRT1 is implicated in the
regulation of glucose metabolism and insulin sensitivity we
thought that studying the associated disorders in SIRT1 might be
beneficial. Our results showed that SIRT1 level and activity were
decreased by 54.84% and 55.81% respectively in the liver and by
59.30% and 63.71% respectively in the pancreas of diabetic rats.
Remarkably, there was marked pancreatic apoptosis after induc-
tion of diabetes.
Our results were in agreement with Suvarna50 who found that
the nutrients availability such as high serum glucose in diabetic
rats are associated with decreased levels of NAD/NADH+- which
are the main activators of SIRT1- leading to decreased SIRT1
release and activity.
However, we could not specify if the decrease in SIRT1 shared
partially in the development of hyperglycemia and IR or the STZ-
induced T2DM was the initial cause of the observed decrease in
SIRT1.
Meanwhile, our results in GpII revealed that the elevated serum
glucose, insulin, HOMA and TG were parallel to the decline in SIRT1
level and activity (inverse correlation). Regarding the changes in
serum HDL and SIRT1, both showed a positive correlation.
Data could be explained by Sebastián et al.49 who suggested
that a combination of over-nutrition, inactivity, genetic and other
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leads to dysregulation of AMPK and SIRT1. This in turn could lead
to insulin resistance, subsequent hyperinsulinemia, mitochondrial
dysfunction, and abnormalities in cellular lipid metabolism.
Wang et al.54 showed that hepatic-specific deletion of SIRT1,
lead to hepatic glucose overproduction and hyperglycemia. The
resulting increase in ROS impairs insulin signaling in insulin-
sensitive tissues, such as adipose tissues and muscles, leading to
insulin resistance.
In addition, Bordone et al.3 showed that a reduction in SIRT1
levels reduces the capacity of b-cells to secrete insulin in response
to glucose. This fact was explained by Rogina and Helfand47 who
noticed elevated levels of UCP2 in cells with reduced SIRT1. Thus
ATP synthesis was reduced lowering the amplitude of insulin
induction by glucose.
Metformin has been shown to be highly effective in delaying or
preventing T2DM in those having IGT.13 Parallel, in our study, rats
administered metformin (120 mg/kg) once daily for a period of one
month before induction of diabetes, showed significant decrease in
their BMI%, serum glucose level, serum insulin level and HOMA
when compared to diabetic group (GpII).
The diabetes prevention program (DPP) demonstrated that
intervention with metformin decreased the development of
diabetes in adults with impaired glucose tolerance by 31%.15
Also, Mark et al.37 were in agreement with our results who
demonstrated that metformin administration to normal rats is cap-
able of preventing the development of acute lipid-induced insulin
resistance. The primary effect of metformin was amelioration of
the lipid-impaired insulin suppressibility of HGO; thus, the liver
would seem to be the principal target tissue for this prophylactic
effect.
In the same context, Mithieux et al.38 reported that in hyper-
insulinemiceuglycemic clamping (HEC) conditions, metformin pre-
treatment resulted in increased storage of liver glycogen, in high-
fat–fed rats, suggesting that metformin attenuated glycogenolysis
or enhanced glycogen synthesis, perhaps from gluconeogenic
substrates.
On the other hand, Kim et al.29 examined chronically insulin-
resistant high-fat–fed rats under HEC conditions and demonstrated
adverse effects on HGO before the manifestation of attenuated
peripheral glucose disposal. There was no accompanying reduction
in triacylglycerol storage in liver after acute lipid infusion and HEC
suggesting that this is not the primary mechanism for the effect of
metformin on HGO.
Scientists have implicated enhancement of liver signaling in the
mechanism of metformin effect, as the drug induced increases in
AMPK activity along with reduced JNK protein21 and in skeletal
muscle of individuals with T2DM after 4 weeks’ administration of
the drug.40
In contrast, no effect of metformin was detected on AMPK activ-
ity in red or white muscle or a central fat depot, consistent with a
lack of effect of the drug on peripheral glucose disposal.37 There-
fore, Samuel et al.48 suggested that the effects of metformin on glu-
coneogenesis may be in part mediated through its effects on other
important gluconeogenic enzymes, such as pyruvate carboxylase,
pyruvate kinase or glucose 6-phosphatase.
Overall, these findings may help in explaining the prophylactic
effect of metformin to oppose further deterioration in gluco-
regulation in humans with impaired glucose tolerance or obesity31
and in implicating enhanced liver signaling in the therapeutic
mechanism of action of metformin.
Similar to its beneficial effects on BMI%, serum glucose, insulin
and HOMA, when given for 1 month before induction of diabetes in
GpIII, metformin was also found to significantly reduced the serum
TG level and the serum HDL level was increased significantly rela-
tive to diabetic rats in GpII.Our results were in agreement with Goldberg et al.23 who
reported that metformin modestly reduced small and dense LDL
and raised small and large HDL. They suggested that the effect of
metformin to increase small HDL was independent of adiponectin,
BMI, and insulin resistance. These findings support the notion that
metformin use may be considered as prophylactic therapy aimed
at lowering cardiovascular risk factors.2
Furthermore, this study showed that metformin administration
over 1 month before induction of diabetes was associated with less
reduction in the level and activity of SIRT1 in liver than that
occurred in diabetic rats. Additionally, no apoptotic changes were
detected in the pancreas of GpIII.
Yoshizaki et al.57 suggested that this cross talk between met-
formin and SIRT1 may be of additive role in protection against obe-
sity, dyslipidemia, pancreatic inflammation, apoptosis and IR thus
preventing or at least delaying the occurrence of T2DM.
Interestingly, our results revealed that the significant increase
in SIRT1 was associated with significant increase in HDL level
(+ve correlation) although it was negatively correlated with BMI
%, serum levels of glucose, insulin, TG and HOMA.
However, it is not clear whether metformin improved hyper-
glycemia and hence spared SIRT1 from the negative feedback of
the low levels of NAD+/NADH or metformin activated SIRT1 via
AMPK signaling pathway which in turn improved diabetes
mellitus. In support, there is a striking resemblance between the
pleiotropic effects of metformin and the physiological features of
SIRT1 activation.55 In both cases reduced inflammation and
oxidative stress, weight loss, improvement in plasma lipid profile
as well as reduced the beta cells destruction (apoptosis) take
place.56
Our study tried to evaluate which of the pre- or post-diabetic
metformin was more beneficial? Undoubtly, metformin has been
in wide clinical use for the alleviation of the hyperglycemia associ-
ated with T2DM for decades.44 Concomitant with this, our results
showed that fasting serum glucose level (mmol/L), fasting serum
insulin level (mIU/L) and HOMA were significantly decreased in
GpIV compared to GpII. Meanwhile, BMI% was insignificantly
decreased in GpIV compared to GpII.
Despite this, a comprehensive molecular basis for the antihy-
perglycemic mechanism of action of metformin has yet to be
established. Whereas Kumar and Dey33 reported that metformin
was shown to ameliorate defects in insulin signaling in vitro,
involving activation of IRSs and associated phosphatidyl inositol
3 kinase activity.
In addition, metformin activates AMPK in hepatocytes,21
whereas enzyme activity was elevated in skeletal muscle of dia-
betic patients after 4 weeks of metformin treatment.40
Metformin treatment also had positive effects on the insulin
signaling pathway in the liver.36 Metformin induces reductions in
JNKs which have been shown to phosphorylate IRS-1 in vitro thus
reducing its activity. This could be important in mediating the abil-
ity of metformin to reduce the impact of lipid infusion on insulin
action in the liver.27
Our study revealed that the serum HDL level was significantly
higher in GpIV (DM + metformin) relative to diabetic GpII. More-
over, the serum TG level in GpIV was significantly decreased rela-
tive to GpII.
Our results were in agreement with Afzal et al.1 who observed
a significant elevation in the level of TG and reduction in HDL in
the animals exposed to intraperitoneal administration of
chemical carcinogen diethyl nitrosamine, when compared to a
normal control but these parameters were maintained to
normal by the treatment of metformin. Also, Rautio et al.45
reported that metformin was effective in improving several
parameters of lipid profile in T2DM and non-diabetics with coro-
nary heart disease.
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T2DM and non-diabetics with central fat distribution, metformin
reduced cholesterol but not triglycerides. Fleming et al.20 revealed
that metformin use in women with PCOS have demonstrated an
improvement of HDL but no significant effect on total cholesterol
or triglycerides.
The divergence of the findings among these studies may be
related to the characteristics of the population studied; thus, for
example metformin may be more effective in more hyperinsuline-
mic and/or obese populations.
As observed in our work, metformin intake for 1 month after
induction of diabetes induced a significant enhancement in SIRT1
level and activity in the liver and pancreas of diabetic rats relative
to diabetic group (GpII). Our results showed significant elevation of
SIRT1 level and activity in pancreas in GpIV relative to GpII. In
addition the pancreatic apoptosis was disappeared.
Metformin has been reported to activate AMPK. Canto et al.7
suggested that AMPK can increase SIRT1 activity potentially
through an AMPK-mediated increase in the transcription of
(NAMPT), the rate-limiting enzyme of the salvage pathway for
NAD+, an essential co-factor for SIRT1 activity. Additionally, Hou
et al.24 have reported that SIRT1 can deacetylate and activate
LKB1, leading to the activation of AMPK. This raises the possibility
that a positive feedback system could be operative in response to
hyperglycaemia following metformin administration.
Interestingly, Lee et al.34 found that metformin-treated cells
produced a lower amount of NO than control cells, which leads
to resistance to cytokine toxicity. Authors also suggested that met-
formin through activation of SIRT1 plays a cytoprotective role
against cytokine in pancreatic b-cells. SIRT1 might deacetylate
non-histone proteins such as NF-jB protecting pancreatic islets
from cytokine toxicity.
Finally, we should ask which was more beneficial: pre- or post-
diabetic metformin? Unexpectedly, data in our work found no sig-
nificant difference between the effect of metformin pre- or post-
diabetic regarding BMI%, serum glucose, insulin, HDL, HOMA and
pancreatic apoptosis, while serum TG level was significantly lower
in GpIV.
Notably, when we compare the effect of metformin versus the
effect of caloric restriction CR used in our previous publication,18
we did not detect any significant difference between the effect of
metformin or CR (either before or after) induction of diabetes on
all the studied parameters which may be explained by Dhahbi
et al.14 who proposed that metformin is CR mimetic. They found
that mice administered the drug exhibit similar gene expression
changes as CR mice.
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